LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

Kodu・Aktsiate loetelu・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Avatud

SektorTervishoid

34.21 3.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.59

Max

34.59

Põhinäitajad
By Trading Economics
Sissetulek	-5M -128M
Müük	6.8M 11M
Aktsiakasum	-1.23
Kasumimarginaal	-1,191.029
Töötajad	594
EBITDA	-18M -139M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+166.36% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-710M 3.6B
Eelmine avamishind	30.61
Eelmine sulgemishind	34.21

Uudiste sentiment

By Acuity

94%

1 / 344 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuni 2026, 23:22 UTC

Tulu

Suurimad hinnamuutused turgudel

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3. juuni 2026, 23:09 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3. juuni 2026, 20:51 UTC

Tulu

Costco Reports 15% Sales Growth in May

3. juuni 2026, 20:43 UTC

Tulu

Broadcom 2Q Revenue Climbs on AI Chip Demand

3. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3. juuni 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. juuni 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3. juuni 2026, 23:15 UTC

Market Talk

Tulu

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3. juuni 2026, 22:08 UTC

Kuumad aktsiad

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3. juuni 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3. juuni 2026, 21:18 UTC

Tulu

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3. juuni 2026, 21:15 UTC

Tulu

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3. juuni 2026, 21:13 UTC

Tulu

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3. juuni 2026, 21:13 UTC

Tulu

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3. juuni 2026, 21:12 UTC

Tulu

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3. juuni 2026, 21:09 UTC

Tulu

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3. juuni 2026, 21:03 UTC

Tulu

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. juuni 2026, 20:43 UTC

Tulu

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3. juuni 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3. juuni 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3. juuni 2026, 20:35 UTC

Tulu

Broadcom Stock Falls Despite Record Results -- Barrons.com

3. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3. juuni 2026, 20:17 UTC

Tulu

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3. juuni 2026, 20:17 UTC

Tulu

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Adj EPS $2.44 >AVGO

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q EPS $1.91 >AVGO

3. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Rev $22.19B >AVGO

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

166.36% tõus

12 kuu keskmine prognoos

Keskmine 88.14 USD 166.36%

Kõrge 97 USD

Madal 81 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Crinetics Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

1 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.